Evolus Inc. Investor Presentation June 2022

Evolus presents its commercial strategy for Jeuveau®, a botulinum toxin product, and discusses Phase II clinical trial plans for an extra-strength formulation. The presentation outlines market growth potential, product adoption, revenue expectations, and regulatory compliance related to its settlement agreements with Allergan and Medytox.